F.A.Z. Konferenz 15. Jahrestagung House of Pharma & Healthcare

F.A.Z. Konferenz 15. Jahrestagung House of Pharma & Healthcare
Go back

Die Jahrestagung House of Pharma & Healthcare ist eine der führenden Pharmakonferenzen Deutschlands.

Sie bietet Experten aus allen Bereichen der Gesundheits- und Pharmabranche die Gelegenheit zur Information und Vernetzung, denn Sie bindet im Programm alle Akteure des Gesundheitswesens ein: Politiker wie Patienten, Ärzte und Apotheker, Krankenkassen und Zulassungsbehörden, aber auch Unternehmen, Universitäten und Forschungsinstitute. Im Rahmen von zahlreichen Vorträgen, Podiumsdiskussionen und Workshop-Sessions wird intensiv nach Lösungen aktueller Probleme der Arzneimittelforschung, Patientenversorgung und Gesundheitspolitik gesucht.

Exklusivitätsvorbehalt

Die Jahrestagung House of Pharma & Healthcare richtet sich an Entscheiderinnen und Entscheider aus pharmazeutischer Industrie und Biotechnologie, Pharmaforschung und klinischer Entwicklung, Gesundheitswesen und Krankenkassen, Medizintechnik und Diagnostik, Politik und Regulatorik, Verbänden und Organisationen sowie HealthTech- und BioTech-Unternehmen. Für diesen Personenkreis ist die Teilnahme kostenfrei.

 

Free Participation for BioRN members.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code / Registration Form and more Information.

register now

Our latest News

discover more
Vaccine Against Brain Tumors Shows Promising Long-Term Results

Vaccine Against Brain Tumors Shows Promising Long-Term Results

A novel vaccination strategy against certain malignant brain tumors could fundamentally improve treatment for patients. Researchers from the German Cancer Research Center (DKFZ), Mannheim University Medical Center, Heidelberg University Hospital, and numerous partner institutions* have published encouraging long-term results from a clinical trial involving a vaccine that activates the immune system against a common genetic […]

read more
VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

VectorBuilder Partners with MaxCyte® to Advance Clinical-Grade Cell Engineering

The next-generation platform integrates VectorBuilder’s regulatory-compliant gene delivery technology with MaxCyte’s clinically validated electroporation platform to enable robust, scalable, and reliable clinical-grade cell engineering. Chicago, IL & Rockville, MD – June 23, 2026 – VectorBuilder, a global leader in gene delivery technologies and CDMO services, and MaxCyte, a leading, cell-engineering company providing enabling platform technologies to […]

read more
LEEI-Platform eFIT is Available to Industry and Research

LEEI-Platform eFIT is Available to Industry and Research

KyooBe Tech is making its innovative vaccine development platform available to industry and research partners:Enabling faster and scalable vaccine production using Low-Energy Electron Irradiation (LEEI). Flexible Vaccine Manufacturing for Emerging Infectious Diseases Recent infectious disease events—from hantavirus outbreaks and meningitis cases to recurring disease outbreaks in livestock farming—highlight the need for flexibly scalable vaccine manufacturing […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp